바이러스 벡터 및 플라스미드 DNA 제조 시장 : 성장, 미래 전망, 경쟁 분석(2023-2031년)

The viral vectors and plasmid DNA manufacturing market is expected to grow at a CAGR of 22.5% during the forecast period of 2023 to 2031, driven by the increasing demand for advanced gene therapies, vaccines, and cell-based therapies. The market revenue is expected to witness substantial growth in the coming years, with a promising compound annual growth rate (CAGR).Viral vectors and plasmid DNA are essential components in the development and production of gene therapies and vaccines. Viral vectors, such as adenoviruses, lentiviruses, and adeno-associated viruses (AAVs), are used to deliver genetic material into target cells, enabling the modification or correction of specific genes associated with various diseases. Plasmid DNA, on the other hand, serves as a vehicle for carrying therapeutic genes, providing the necessary instructions for protein synthesis within cells.The market for viral vectors and plasmid DNA manufacturing is driven by advancements in biotechnology and genetic engineering, which have revolutionized the field of medicine. Gene therapies have shown tremendous potential in treating a range of genetic disorders, rare diseases, and certain types of cancer. Additionally, the development of vaccines targeting infectious diseases and immunotherapies for cancer has further propelled the demand for viral vectors and plasmid DNA manufacturing.The COVID-19 pandemic has further accelerated the growth of this market, with a surge in research and development activities to develop vaccines and treatments. Several pharmaceutical companies and research organizations have focused their efforts on leveraging viral vectors and plasmid DNA to develop COVID-19 vaccines and therapeutics. This unprecedented global health crisis has highlighted the importance of viral vectors and plasmid DNA manufacturing capabilities in addressing emerging infectious diseases and public health challenges.

Growing Demand for Gene Therapies

The viral vectors and plasmid DNA manufacturing market is driven by the growing demand for gene therapies. Gene therapy offers a promising approach to treat a wide range of genetic disorders and inherited diseases by introducing functional genes into patients' cells. The increasing prevalence of genetic diseases, such as muscular dystrophy, cystic fibrosis, and hemophilia, has fuelled the demand for gene therapies. According to a study published in the Journal of the American Medical Association (JAMA), gene therapy has shown significant therapeutic benefits in clinical trials for various genetic disorders. The success of gene therapies in treating diseases that were previously untreatable or had limited treatment options has generated a strong market demand for viral vectors and plasmid DNA used in their manufacturing.

Advancements in Viral Vector Technology

Advancements in viral vector technology play a crucial role in driving the growth of the viral vectors and plasmid DNA manufacturing market. Researchers and biopharmaceutical companies are constantly working on improving the efficiency, safety, and specificity of viral vectors used in gene therapies and vaccines. For example, the development of new generation adeno-associated viruses (AAVs) with enhanced transduction capabilities and reduced immunogenicity has contributed to the success of several gene therapy trials. A study published in the journal Molecular Therapy demonstrated the potential of novel AAV variants in achieving efficient gene delivery. These advancements in viral vector technology have not only improved the efficacy of gene therapies but also expanded their application in various therapeutic areas, further driving the demand for viral vectors and plasmid DNA manufacturing.

Increasing Investments in Biotechnology Research and Development

The viral vectors and plasmid DNA manufacturing market is propelled by increasing investments in biotechnology research and development. Governments, pharmaceutical companies, and research institutions are allocating significant funds for the development of innovative therapies, including gene therapies and vaccines. For instance, the National Institutes of Health (NIH) in the United States has invested substantial resources in supporting gene therapy research and clinical trials. The European Union has also committed significant funding through its Horizon 2020 program for advancing biotechnology and gene therapy initiatives. These investments in research and development activities fuel the discovery of novel viral vectors and plasmid DNA manufacturing technologies, leading to the commercialization of advanced therapies. The growing financial support and focus on biotechnology research and development are expected to drive the viral vectors and plasmid DNA manufacturing market in the coming years.

Regulatory Challenges and Safety Concerns

The viral vectors and plasmid DNA manufacturing market faces regulatory challenges and safety concerns that serve as a restraint to its growth. The development and commercialization of gene therapies and vaccines involve stringent regulatory processes and safety assessments to ensure the efficacy and safety of these products. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), impose strict guidelines and requirements for the manufacturing, quality control, and clinical testing of viral vectors and plasmid DNA. Compliance with these regulations can be time-consuming and expensive for manufacturers, leading to delays in product approvals and market entry. Additionally, concerns about the potential risks associated with gene therapies, such as immune responses, off-target effects, and long-term safety profiles, pose challenges to the widespread adoption of these therapies. Reports of adverse events and safety issues in clinical trials can impact the perception and acceptance of gene therapies, affecting the demand for viral vectors and plasmid DNA manufacturing. For example, the safety concerns surrounding a gene therapy trial for the treatment of X-linked severe combined immunodeficiency (X-SCID) led to a temporary halt in the trial. These regulatory challenges and safety concerns pose a restraint to the viral vectors and plasmid DNA manufacturing market, necessitating rigorous compliance with regulations and continued research to ensure the safety and efficacy of gene therapies and vaccines.

Adenovirus Vectors Dominates the Market by Vector Type

The viral vectors and plasmid DNA manufacturing market can be segmented based on vector types, including adenovirus, retrovirus, adeno-associated virus (AAV), lentivirus, plasmids, and others. Among these, AAV is expected to witness the highest CAGR during the forecast period of 2023 to 2031. AAV vectors have gained significant attention in gene therapy applications due to their ability to efficiently deliver therapeutic genes to target cells with low immunogenicity and long-term gene expression. The use of AAV vectors in approved gene therapies, such as Luxturna and Zolgensma, has showcased their potential in treating inherited genetic disorders. As a result, the demand for AAV vectors is increasing, driving the growth of the market in terms of CAGR. In terms of revenue, adenovirus vectors held the highest share in 2022 in the viral vectors and plasmid DNA manufacturing market. Adenovirus vectors are widely used in gene therapy research and clinical trials due to their high transduction efficiency and ability to accommodate large DNA inserts. They have demonstrated success in several gene therapy applications, particularly in cancer immunotherapies and vaccine development. Moreover, the robust manufacturing processes and well-established protocols for adenovirus vectors contribute to their dominant revenue position in the market. Retrovirus vectors, including lentivirus, also hold a significant revenue share, primarily driven by their use in CAR-T cell therapies and gene-modified cell therapies. Plasmids, which serve as essential tools in gene cloning and recombinant DNA technology, contribute to the market's revenue but have a comparatively lower growth rate. Other vector types, such as herpes simplex virus (HSV) vectors and vaccinia virus vectors, hold a smaller revenue share in the market. In summary, while adenovirus vectors generate the highest revenue, AAV vectors are expected to witness the highest CAGR, driven by their promising applications in gene therapies.

North America Leads the Revenues While APAC Leads the Growth

North America held a significant share in terms of revenue in the viral vectors and plasmid DNA manufacturing market in 2022. The region has a well-established biopharmaceutical industry, robust research infrastructure, and favorable regulatory frameworks that facilitate the development and commercialization of gene therapies and vaccines. Moreover, increasing investments in research and development activities, particularly in the United States, contribute to the market's revenue growth. Europe is also a prominent region in the viral vectors and plasmid DNA manufacturing market, with a significant revenue contribution. The presence of leading biopharmaceutical companies, advancements in biotechnology research, and strong government support drive the market's growth in this region. In terms of the highest CAGR during the forecast period of 2023 to 2031, Asia Pacific is expected to top the ranl. The region has witnessed rapid growth in the biotechnology sector, driven by factors such as increasing investments in research and development, rising healthcare expenditure, and a growing focus on personalized medicine. Countries like China, Japan, and India are emerging as key players in the viral vectors and plasmid DNA manufacturing market, leveraging their scientific expertise and expanding biopharmaceutical capabilities. Latin America and the Middle East and Africa regions are also witnessing steady growth in the market, driven by the increasing focus on improving healthcare infrastructure and the adoption of advanced medical technologies.

Market Competition to Intensify During the Forecast Period

The viral vectors and plasmid DNA manufacturing market is highly competitive, with several key players actively participating in the development and production of viral vectors and plasmid DNA for gene therapies and vaccines. These companies are focusing on strategic initiatives to strengthen their market presence and gain a competitive edge.One of the top players in the market is Lonza Group, a global contract development and manufacturing organization (CDMO). Lonza offers a wide range of services, including viral vector manufacturing, plasmid DNA production, and process development.Key strategies adopted by top players and others in the market include investing in research and development activities to enhance manufacturing processes, expanding production capacity to meet the growing demand, and establishing strategic partnerships and collaborations to access novel technologies and broaden their market reach. These companies are also focusing on ensuring regulatory compliance, quality assurance, and adherence to good manufacturing practices to meet the stringent requirements of the gene therapy and vaccine industry. Moreover, competition in the viral vectors and plasmid DNA manufacturing market is further intensified by emerging players and start-ups that are entering the market with innovative technologies and platforms. These players are leveraging advancements in biotechnology and genetic engineering to develop novel viral vectors and plasmid DNA manufacturing approaches.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation ofViral Vectors and Plasmid DNA Manufacturing market are as follows:

• Research and development budgets of manufacturers and government spending

• Revenues of key companies in the market segment

• Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Viral Vectors and Plasmid DNA Manufacturing market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Vector Type

Adenovirus

Retrovirus

Adeno-Associated Virus (AAV)

Lentivirus

Plasmids

Others

Workflow

Upstream Manufacturing

Vector Amplification & Expansion

Vector Recovery/Harvesting

Downstream Manufacturing

Purification

Fill Finish

Application

Antisense & RNAi Therapy

Gene Therapy

Cell Therapy

Vaccinology

Research Applications

End-use

Pharmaceutical and Biopharmaceutical Companies

Research Institutes

Disease

Cancer

Genetic Disorders

Infectious Diseases

Others

Region Segment (2021-2031; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Key questions answered in this report:

• What are the key micro and macro environmental factors that are impacting the growth of Viral Vectors and Plasmid DNA Manufacturing market?

• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

• Estimated forecast and market projections up to 2031.

• Which segment accounts for the fastest CAGR during the forecast period?

• Which market segment holds a larger market share and why?

• Are low and middle-income economies investing in the Viral Vectors and Plasmid DNA Manufacturing market?

• Which is the largest regional market for Viral Vectors and Plasmid DNA Manufacturing market?

• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

• Which are the key trends driving Viral Vectors and Plasmid DNA Manufacturing market growth?

• Who are the key competitors and what are their key strategies to enhance their market presence in the Viral Vectors and Plasmid DNA Manufacturing market worldwide?

Table of Contents

1. Preface

• 1.1. Report Description
  • 1.1.1. Purpose of the Report
  • 1.1.2. Target Audience
  • 1.1.3. Key Offerings
• 1.2. Market Segmentation
• 1.3. Research Methodology
  • 1.3.1. Phase I - Secondary Research
  • 1.3.2. Phase II - Primary Research
  • 1.3.3. Phase III - Expert Panel Review
  • 1.3.4. Assumptions
  • 1.3.5. Approach Adopted

2. Executive Summary

• 2.1. Market Snapshot: Global Viral Vectors and Plasmid DNA Manufacturing Market
• 2.2. Global Viral Vectors and Plasmid DNA Manufacturing Market, By Vector Type, 2022 (US$ Million)
• 2.3. Global Viral Vectors and Plasmid DNA Manufacturing Market, By Workflow, 2022 (US$ Million)
• 2.4. Global Viral Vectors and Plasmid DNA Manufacturing Market, By Application, 2022 (US$ Million)
• 2.5. Global Viral Vectors and Plasmid DNA Manufacturing Market, By End-use, 2022 (US$ Million)
• 2.6. Global Viral Vectors and Plasmid DNA Manufacturing Market, By Disease, 2022 (US$ Million)
• 2.7. Global Viral Vectors and Plasmid DNA Manufacturing Market, By Geography, 2022 (US$ Million)
• 2.8. Attractive Investment Proposition by Geography, 2022

3. Viral Vectors and Plasmid DNA Manufacturing Market: Competitive Analysis

• 3.1. Market Positioning of Key Viral Vectors and Plasmid DNA Manufacturing Market Vendors
• 3.2. Strategies Adopted by Viral Vectors and Plasmid DNA Manufacturing Market Vendors
• 3.3. Key Industry Strategies
• 3.4. Tier Analysis 2022 Versus 2031

4. Viral Vectors and Plasmid DNA Manufacturing Market: Macro Analysis & Market Dynamics

• 4.1. Introduction
• 4.2. Global Viral Vectors and Plasmid DNA Manufacturing Market Value, 2021 - 2031, (US$ Million)
• 4.3. Market Dynamics
  • 4.3.1. Market Drivers
  • 4.3.2. Market Restraints
  • 4.3.3. Key Challenges
  • 4.3.4. Key Opportunities
• 4.4. Impact Analysis of Drivers and Restraints
• 4.5. See-Saw Analysis

5. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)

• 5.1. Market Overview
• 5.2. Growth & Revenue Analysis: 2022 Versus 2031
• 5.3. Market Segmentation
  • 5.3.1. Adenovirus
  • 5.3.2. Retrovirus
  • 5.3.3. Adeno-Associated Virus (AAV)
  • 5.3.4. Lentivirus
  • 5.3.5. Plasmids
  • 5.3.6. Others

6. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)

• 6.1. Market Overview
• 6.2. Growth & Revenue Analysis: 2022 Versus 2031
• 6.3. Market Segmentation
  • 6.3.1. Upstream Manufacturing
    • 6.3.1.1. Vector Amplification & Expansion
    • 6.3.1.2. Vector Recovery/Harvesting
  • 6.3.2. Downstream Manufacturing
    • 6.3.2.1. Purification
    • 6.3.2.2. Fill Finish

7. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)

• 7.1. Market Overview
• 7.2. Growth & Revenue Analysis: 2022 Versus 2031
• 7.3. Market Segmentation
  • 7.3.1. Antisense & RNAi Therapy
  • 7.3.2. Gene Therapy
  • 7.3.3. Cell Therapy
  • 7.3.4. Vaccinology
  • 7.3.5. Research Applications

8. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)

• 8.1. Market Overview
• 8.2. Growth & Revenue Analysis: 2022 Versus 2031
• 8.3. Market Segmentation
  • 8.3.1. Pharmaceutical and Biopharmaceutical Companies
  • 8.3.2. Research Institutes

9. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)

• 9.1. Market Overview
• 9.2. Growth & Revenue Analysis: 2022 Versus 2031
• 9.3. Market Segmentation
  • 9.3.1. Cancer
  • 9.3.2. Genetic Disorders
  • 9.3.3. Infectious Diseases
  • 9.3.4. Others

10. North America Viral Vectors and Plasmid DNA Manufacturing Market, 2021-2031, USD (Million)

• 10.1. Market Overview
• 10.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
• 10.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
• 10.4. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
• 10.5. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
• 10.6. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
• 10.7.Viral Vectors and Plasmid DNA Manufacturing Market: By Region, 2021-2031, USD (Million)
  • 10.7.1.North America
    • 10.7.1.1. U.S.
      • 10.7.1.1.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
      • 10.7.1.1.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
      • 10.7.1.1.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 10.7.1.1.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
      • 10.7.1.1.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
    • 10.7.1.2. Canada
      • 10.7.1.2.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
      • 10.7.1.2.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
      • 10.7.1.2.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 10.7.1.2.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
      • 10.7.1.2.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
    • 10.7.1.3. Rest of North America
      • 10.7.1.3.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
      • 10.7.1.3.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
      • 10.7.1.3.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 10.7.1.3.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
      • 10.7.1.3.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)

11. UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market, 2021-2031, USD (Million)

• 11.1. Market Overview
• 11.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
• 11.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
• 11.4. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
• 11.5. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
• 11.6. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
• 11.7.Viral Vectors and Plasmid DNA Manufacturing Market: By Region, 2021-2031, USD (Million)
  • 11.7.1.UK and European Union
    • 11.7.1.1. UK
      • 11.7.1.1.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
      • 11.7.1.1.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
      • 11.7.1.1.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 11.7.1.1.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
      • 11.7.1.1.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
    • 11.7.1.2. Germany
      • 11.7.1.2.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
      • 11.7.1.2.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
      • 11.7.1.2.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 11.7.1.2.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
      • 11.7.1.2.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
    • 11.7.1.3. Spain
      • 11.7.1.3.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
      • 11.7.1.3.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
      • 11.7.1.3.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 11.7.1.3.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
      • 11.7.1.3.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
    • 11.7.1.4. Italy
      • 11.7.1.4.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
      • 11.7.1.4.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
      • 11.7.1.4.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 11.7.1.4.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
      • 11.7.1.4.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
    • 11.7.1.5. France
      • 11.7.1.5.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
      • 11.7.1.5.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
      • 11.7.1.5.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 11.7.1.5.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
      • 11.7.1.5.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
    • 11.7.1.6. Rest of Europe
      • 11.7.1.6.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
      • 11.7.1.6.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
      • 11.7.1.6.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 11.7.1.6.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
      • 11.7.1.6.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)

12. Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market, 2021-2031, USD (Million)

• 12.1. Market Overview
• 12.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
• 12.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
• 12.4. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
• 12.5. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
• 12.6. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
• 12.7.Viral Vectors and Plasmid DNA Manufacturing Market: By Region, 2021-2031, USD (Million)
  • 12.7.1.Asia Pacific
    • 12.7.1.1. China
      • 12.7.1.1.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
      • 12.7.1.1.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
      • 12.7.1.1.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 12.7.1.1.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
      • 12.7.1.1.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
    • 12.7.1.2. Japan
      • 12.7.1.2.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
      • 12.7.1.2.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
      • 12.7.1.2.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 12.7.1.2.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
      • 12.7.1.2.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
    • 12.7.1.3. India
      • 12.7.1.3.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
      • 12.7.1.3.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
      • 12.7.1.3.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 12.7.1.3.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
      • 12.7.1.3.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
    • 12.7.1.4. Australia
      • 12.7.1.4.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
      • 12.7.1.4.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
      • 12.7.1.4.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 12.7.1.4.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
      • 12.7.1.4.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
    • 12.7.1.5. South Korea
      • 12.7.1.5.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
      • 12.7.1.5.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
      • 12.7.1.5.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 12.7.1.5.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
      • 12.7.1.5.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
    • 12.7.1.6. Rest of Asia Pacific
      • 12.7.1.6.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
      • 12.7.1.6.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
      • 12.7.1.6.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 12.7.1.6.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
      • 12.7.1.6.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)

13. Latin America Viral Vectors and Plasmid DNA Manufacturing Market, 2021-2031, USD (Million)

• 13.1. Market Overview
• 13.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
• 13.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
• 13.4. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
• 13.5. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
• 13.6. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
• 13.7.Viral Vectors and Plasmid DNA Manufacturing Market: By Region, 2021-2031, USD (Million)
  • 13.7.1.Latin America
    • 13.7.1.1. Brazil
      • 13.7.1.1.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
      • 13.7.1.1.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
      • 13.7.1.1.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 13.7.1.1.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
      • 13.7.1.1.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
    • 13.7.1.2. Mexico
      • 13.7.1.2.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
      • 13.7.1.2.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
      • 13.7.1.2.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 13.7.1.2.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
      • 13.7.1.2.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
    • 13.7.1.3. Rest of Latin America
      • 13.7.1.3.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
      • 13.7.1.3.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
      • 13.7.1.3.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 13.7.1.3.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
      • 13.7.1.3.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)

14. Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market, 2021-2031, USD (Million)

• 14.1. Market Overview
• 14.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
• 14.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
• 14.4. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
• 14.5. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
• 14.6. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
• 14.7.Viral Vectors and Plasmid DNA Manufacturing Market: By Region, 2021-2031, USD (Million)
  • 14.7.1.Middle East and Africa
    • 14.7.1.1. GCC
      • 14.7.1.1.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
      • 14.7.1.1.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
      • 14.7.1.1.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 14.7.1.1.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
      • 14.7.1.1.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
    • 14.7.1.2. Africa
      • 14.7.1.2.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
      • 14.7.1.2.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
      • 14.7.1.2.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 14.7.1.2.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
      • 14.7.1.2.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
    • 14.7.1.3. Rest of Middle East and Africa
      • 14.7.1.3.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
      • 14.7.1.3.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
      • 14.7.1.3.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 14.7.1.3.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
      • 14.7.1.3.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)

15. Company Profile

• 15.1. Lonza
  • 15.1.1. Company Overview
  • 15.1.2. Financial Performance
  • 15.1.3. Product Portfolio
  • 15.1.4. Strategic Initiatives
• 15.2. Catapult
  • 15.2.1. Company Overview
  • 15.2.2. Financial Performance
  • 15.2.3. Product Portfolio
  • 15.2.4. Strategic Initiatives
• 15.3. uniQure N.V.
  • 15.3.1. Company Overview
  • 15.3.2. Financial Performance
  • 15.3.3. Product Portfolio
  • 15.3.4. Strategic Initiatives
• 15.4. FUJIFILM Diosynth Biotechnologies
  • 15.4.1. Company Overview
  • 15.4.2. Financial Performance
  • 15.4.3. Product Portfolio
  • 15.4.4. Strategic Initiatives
• 15.5. Kaneka Eurogentec S.A.
  • 15.5.1. Company Overview
  • 15.5.2. Financial Performance
  • 15.5.3. Product Portfolio
  • 15.5.4. Strategic Initiatives
• 15.6. Oxford Biomedica
  • 15.6.1. Company Overview
  • 15.6.2. Financial Performance
  • 15.6.3. Product Portfolio
  • 15.6.4. Strategic Initiatives
• 15.7. Spark Therapeutics, Inc.
  • 15.7.1. Company Overview
  • 15.7.2. Financial Performance
  • 15.7.3. Product Portfolio
  • 15.7.4. Strategic Initiatives
• 15.8. Cobrabiologics
  • 15.8.1. Company Overview
  • 15.8.2. Financial Performance
  • 15.8.3. Product Portfolio
  • 15.8.4. Strategic Initiatives
• 15.9. Merck KGaA
  • 15.9.1. Company Overview
  • 15.9.2. Financial Performance
  • 15.9.3. Product Portfolio
  • 15.9.4. Strategic Initiatives
• 15.10. Other Notable Players
  • 15.10.1. Company Overview
  • 15.10.2. Financial Performance
  • 15.10.3. Product Portfolio
  • 15.10.4. Strategic Initiatives